Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

Chen, Hong Hwa; Chen, William Tzu Liang; Lee, Hsin Chung; Lin, Jen Kou; Fang, Chuan Yin; Chou, Yenn Hwei; Lin, Peng; Lin, Bo; Huang, Chun‐Chia; Yeh, Chia-Yi; Hsu, Hsi Hsien; Chen, Hung-Chang; Ting, Wen Chien; Yang, Ming‐Chin; Tan, Elise Chia‐Hui

doi:10.1007/s11136-014-0773-x

Cited by 5 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 9 full economic evaluations comparing capecitabine to 5FU in stage III, 6 (67%) concluded capecitabine dominates 5-FU (being less costly and more effective) and 1 (11%) reported cost-effectiveness (more costly but more effective) [ 24 – 32 , 34 , 36 – 41 ]. Of the two remaining studies, Soni et al utilised data from a retrospective cohort study, noting patients receiving capecitabine were older (mean age: 73 vs. 67 years) and less fit (ECOG 2–4: 14.6% vs. 6.3%) [ 33 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review

Gibbs

Tie

et al. 2023

Cost Eff Resour Alloc

View full text Add to dashboard Cite

Objective The aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colon cancer (CC) and identify gaps in the available evidence that might inform further research. Method A systematic review of published economic evaluations was undertaken. Four databases were searched and full-text publications in English were screened for inclusion. A narrative synthesis was performed to summarise the evidence. Results Thirty-eight studies were identified and stratified by cancer stage and AC strategy. The majority (89%) were full economic evaluations considering both health outcomes, usually measured as quality-adjusted life years (QALYs), and costs. AC was found to be cost-effective compared to no AC for both stage II and III CC. Oral and oxaliplatin-based AC was cost-effective for stage III. Three months of CAPOX was cost-effective compared to 6-month in high-risk stage II and stage III CC. Preliminary evidence suggests that biomarker approaches to AC selection in stage II can reduce costs and improve health outcomes. Notably, assessment of QALYs were predominantly reliant on a small number of non-contemporary health-utility studies. Only 32% of studies considered societal costs such as travel and time off work. Conclusions Published economic evaluations consistently supported the use of AC in stage II and III colon cancer. Biomarker-driven approaches to patient selection have great potential to be cost-effective, but more robust clinical and economic evidence is warranted. Patient surveys embedded into clinical trials may address critical knowledge gaps regarding accurate assessment of QALYs and societal costs in the modern era.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Further analyses demonstrated that CAPOX reduced costs compared to FOLFOX with one CUA reported cost-effectiveness in a combined cohort of high-risk stage II and stage III patients [ 26 , 34 , 39 , 40 ].…”

Section: Resultsmentioning

confidence: 99%

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review

Gibbs

Tie

et al. 2023

Cost Eff Resour Alloc

View full text Add to dashboard Cite

show abstract

“…18 3.6 Oral vs. intravenous AC Of the 9 full economic evaluations comparing capecitabine to 5FU in stage III, 6 (67%) concluded capecitabine dominates 5-FU (being less costly and more effective) and 1 (11%) reported costeffectiveness (more costly but more effective). [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] Of the two remaining studies, Soni et al utilised data from a retrospective cohort study, noting patients receiving capecitabine were older (mean age: 73 vs. 67 years) and less t (ECOG 2-4: 14.6% vs. 6.3%). 30 Accordingly, these patients were less likely to receive full intensity of treatment with the authors concluding that capecitabine would be cost-effective if treatment intensity approached 100%.…”

Section: Ac Vs No Acmentioning

confidence: 99%

Section: Ac Vs No Acmentioning

confidence: 99%

Health economic evidence for adjuvant chemotherapy in stage II and III colorectal cancer: a systematic review

Gibbs

Tie

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: The aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colorectal cancer (CRC) and to identify gaps in the available evidence that might inform further research.Method : A systematic review of published economic evaluations was undertaken. Four databases were searched and full-text publications in English were screened for inclusion. A narrative synthesis was performed to summarise the evidence.Results: Thirty-eight studies were identified and stratified by cancer stage and AC strategy. The majority (89%) were full economic evaluations considering both health outcomes, usually measured as quality-adjusted life years (QALYs), and costs. AC was found to be cost-effective compared to no AC for both stage II and III CRC. Oral and oxaliplatin-based AC was cost-effective for stage III. Three months of CAPOX was cost-effective compared to 6-month in high-risk stage II and stage III CRC. Preliminary evidence suggests that biomarker approaches to AC selection in stage II can reduce costs and improve health outcomes. Notably, assessment of QALYs were predominantly reliant on a small number of non-contemporary health-utility studies. Only 32% of studies considered societal costs such as travel and time off work. Conclusions: Published economic evaluations consistently supported the use of AC in stage II and III colorectal cancer. Biomarker-driven approaches to patient selection have great potential to be cost-effective, but more robust clinical and economic evidence is warranted. Patient surveys embedded into clinical trials may address critical knowledge gaps regarding accurate assessment of QALYs and societal costs in the modern era.

show abstract

Comparison of 5–FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis

Zou

Wang

Zhang

2017

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

Abstract: Capecitabine is a reasonable alternative and cost-effective treatment option under current conditions for patients with stage III colorectal cancer.

Cited by 5 publications

References 35 publications

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review

Health economic evidence for adjuvant chemotherapy in stage II and III colorectal cancer: a systematic review

Comparison of 5–FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis

Contact Info

Product

Resources

About